Brought to you by 
J&J's Cilag gets rights to Pozen's migraine drug candidate; deal ends
22 Jan 2016
Executive Summary
Johnson & Johnson’s Cilag AG has licensed exclusive development, manufacturing, and marketing rights in Brazil, Columbia, Ecuador, and Peru to Pozen Inc.’s MT400 (naproxen/sumatriptan) for migraine headaches.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J's Cilag gets rights to Pozen's migraine drug candidate; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice